FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ACTEMRA (tocilizumab) submitted by Genentech, Inc. The supplementary filing status is AP (approved).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Giant Cell Arteritis
• Polyarticular Juvenile Idiopathic Arthritis
• Rheumatoid Arthritis
• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• Actemra (tocilizumab)

Snippet

SUPPL AP for ACTEMRA (TOCILIZUMAB)